Abstract Selected to be Highlighted by the American Academy of
Ophthalmology Organization Committee
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 22, 2018--
Inc. (NYSE American: BTX), a clinical-stage biotechnology company
focused on degenerative diseases, announced today that updated results
from a Phase I/IIa study of its lead product candidate, OpRegen®,
a retinal pigment epithelium cell transplant therapy currently in
development for the treatment of dry age-related macular degeneration
(Dry-AMD), will be presented at the 2018
American Academy of Ophthalmology Annual Meeting (AAO 2018), to be
held at the McCormick Place Convention Center in Chicago, Illinois, USA
(October 27 – 30, 2018). The abstract presentation, entitled, “P1/2a
Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE
Cells in Advanced Dry-Form AMD Patients,” will be presented as part
of the OP02 Retina, Vitreous Original Paper Session on Sunday, October 28th,
2018 between 10:30 AM - 12:30 PM EDT in room S405 by Eyal Banin, MD,
PhD, Professor of Ophthalmology, Director, Center for Retinal and
Macular Degenerations, Department of Ophthalmology at Hadassah-Hebrew
University Medical Center (abstract number PA014). The abstract will
provide updated data from patient cohorts 1 through 3 of the study as
well as outline initial data from patient cohort 4 and has been selected
to be highlighted by the AAO 2018 organization committee.
OpRegen® is a retinal pigment epithelium transplant therapy
in Phase I/IIa development for the treatment of dry age-related macular
degeneration, the leading cause of adult blindness in the developed
world. There were no unexpected serious adverse events reported to date.
OpRegen® consists of a suspension of retinal pigment
epithelial (RPE) cells delivered subretinally as an intraocular
injection. RPE cells are essential components of the back lining of the
retina and function to help nourish the retina including photoreceptors.
OpRegen® has been granted Fast Track designation
from the U.S. Food and Drug Administration. OpRegen®
is a registered trademark of Cell Cure Neurosciences Ltd., a
majority-owned subsidiary of BioTime, Inc.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime’s pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime also has significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE
American: AST) and OncoCyte Corporation (NYSE American: OCX), and a
private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005270/en/
Source: BioTime, Inc.
Ioana C. Hone, 510-871-4188